Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab in complement-inhibitor naïve aHUS patients in China
CTR20230681Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Alexion Pharmaceuticals. Started Mar 2023; status: completed.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on CTR20230681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230681.